Background and Purpose: A proinflammatory prothrombotic state may increase the risk of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH). We studied the relationship of levels of leukocytes, platelets, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) with the development of DCI and with clinical outcome in patients with aneurysmal SAH. Methods: In 125 patients admitted within 72 h after aneurysmal SAH, we dichotomized initial blood levels at their median values and investigated the prediction of DCI with Cox proportional hazard analysis and of poor clinical outcome with logistic regression analysis. We also analyzed concentrations before and after onset of DCI with the paired-samples t test and compared changes with those in patients without DCI. Results: During the development of DCI (unrelated to treatment), patients had a larger increase in counts of platelets (difference 49 × 109/l; 95% CI: 2–98) and leukocytes (difference 2.6 × 109/l; 95% CI: 0.4–5.0) than patients without DCI during the same period. CRP increased during DCI and decreased in patients without DCI (difference 14 mg/l; 95% CI: –29 to 58). ESR increased slightly in both groups (difference 3 mm/h; 95% CI: –15 to 20). None of the determinants at baseline predicted the development of DCI. An increased risk of poor outcome predicted by a high initial leukocyte count (OR 2.5; 95% CI: 1.1–5.7) decreased after adjustment for clinical variables (OR 2.1; 95% CI: 0.8–5.5). Conclusion: Counts of platelets and leukocytes disproportionally increase during the occurrence of DCI after aneurysmal SAH. Drugs with anti-thrombotic or anti-inflammatory properties should be studied for prevention and treatment of DCI.

Keywords:
Subarachnoid hemorrhage, Ischemia, Platelets, Leukocytes
1.
Rabinstein AA, Friedman JA, Weigand SD, McClelland RL, Fulgham JR, Manno EM, Atkinson JL, Wijdicks EF: Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2004;35:1862–1866.
2.
Dumont AS, Dumont RJ, Chow MM, Lin CL, Calisaneller T, Ley KF, Kassell NF, Lee KS: Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery 2003;53:123–135.
3.
Frijns CJM, Fijnheer R, Algra A, van Mourik JA, van Gijn J, Rinkel GJE: Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome. J Neurol Neurosurg Psychiatry 2006;77:77–83.
4.
Teasdale G, Jennett B: Assessment of coma and impaired consciousness: a practical scale. Lancet 1974;2:81–84.
5.
Drake CG: Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg 1988;68:985–986.
6.
Hijdra A, Brouwers PJAM, Vermeulen M, van Gijn J: Grading the amount of blood on computed tomograms after subarachnoid hemorrhage. Stroke 1990;21:1156–1161.
7.
Bamford JM, Sandercock PA, Warlow CP, Slattery J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989;20:828.
8.
Frijns CJM, Kasius KM, Algra A, Fijnheer R, Rinkel GJE: Endothelial cell activation markers and delayed cerebral ischaemia in patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2006;77:863–867.
9.
Ohkuma H, Suzuki S, Kimura M, Sobata E: Role of platelet function in symptomatic cerebral vasospasm following subarachnoid hemorrhage. Stroke 1991;22:854–859.
10.
Juvela S: Cerebral infarction and release of platelet thromboxane after subarachnoid hemorrhage. Neurosurgery 1990;27:929–935.
11.
Juvela S, Hillbom M, Kaste M: Platelet thromboxane release and delayed cerebral ischemia in patients with subarachnoid hemorrhage. J Neurosurg 1991;74:386–392.
12.
Juvela S, Kaste M, Hillbom M: Effect of nimodipine on platelet function in patients with subarachnoid hemorrhage. Stroke 1990;21:1283–1288.
13.
Hirashima Y, Hamada H, Kurimoto M, Origasa H, Endo S: Decrease in platelet count as an independent risk factor for symptomatic vasospasm following subarachnoid hemorrhage. J Neurosurg 2005;102:882–887.
14.
Schafer AI: Thrombocytosis. N Engl J Med 2004;350:1211–1219.
15.
Pyne GJ, Cadoux-Hudson TAD, Clark JF: Platelets play an essential role in the aetiology of cerebral vasospasm after subarachnoid haemorrhage. Med Hypotheses 2003;60:525–530.
16.
Romano JG, Rabinstein AA, Arheart KL, Nathan S, Campo-Bustillo J, Koch S, Korteza AM: Microemboli in aneurysmal subarachnoid hemorrhage. J Neuroimaging 2008;18:396–401.
17.
Spallone A, Acqui M, Pastore FS, Guidetti B: Relationship between leukocytosis and ischemic complications following aneurysmal subarachnoid hemorrhage. Surg Neurol 1987;27:253–258.
18.
McGirt MJ, Mavropoulos JC, McGirt LY, Alexander MJ, Friedman AH, Laskowitz DT, Lynch JR: Leukocytosis as an independent risk factor for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 2003;98:1222–1226.
19.
Dorhout Mees SM, van den Bergh W, Algra A, Rinkel GJE: Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007:006184.
20.
Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsch J, Roth G: Platelet-active drugs: the relationship among dose, effectiveness, and side effects. Chest 2001;119:39S–63S.
21.
Roos EJ, Rinkel GJE, Velthuis BK, Algra A: The relation between aneurysm size and outcome in patients with subarachnoid hemorrhage. Neurology 2000;54:2334–2336.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.